Tango Therapeutics, Inc. Interest Income (Expense), Net
Tango Therapeutics, Inc. (TNGX) reported Interest Income (Expense), Net of $3.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNet · last filed 2026-08-11
- Tango Therapeutics, Inc. interest income (expense), net for the quarter ending 2026-06-30 was $3.72M, a 200.48% increase year-over-year.
- Tango Therapeutics, Inc. interest income (expense), net for the quarter ending 2026-03-31 was $2.18M, a 34.88% increase year-over-year.
- Tango Therapeutics, Inc. interest income (expense), net for the quarter ending 2025-12-31 was $1.68M, a 7.34% decline year-over-year.
- Tango Therapeutics, Inc. interest income (expense), net for the quarter ending 2025-09-30 was $1.10M, a 39.36% decline year-over-year.
- Tango Therapeutics, Inc. interest income (expense), net for fiscal 2025 was $5.63M, a 28.64% decline from fiscal 2024.
- Tango Therapeutics, Inc. interest income (expense), net for fiscal 2024 was $7.89M, a 19.20% increase from fiscal 2023.
- Tango Therapeutics, Inc. interest income (expense), net for fiscal 2023 was $6.62M, a 354.60% increase from fiscal 2022.
- Tango Therapeutics, Inc. interest income (expense), net for fiscal 2022 was $1.46M, a 194.14% increase from fiscal 2021.
| Period end | Interest Income (Expense), Net 3 month | Interest Income (Expense), Net 6 month | Interest Income (Expense), Net 9 month | Interest Income (Expense), Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.72M 10-Q · filed 2026-08-11 | $5.90M 10-Q · filed 2026-08-11 | $7.58M derived: sum of 3 quarters · filed 2026-08-11 | $8.68M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $2.18M 10-Q · filed 2026-05-13 | $3.86M derived: sum of 2 quarters · filed 2026-05-13 | $4.95M derived: sum of 3 quarters · filed 2026-05-13 | $6.19M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.78M derived: sum of 2 quarters · filed 2026-03-05 | $4.02M derived: sum of 3 quarters · filed 2026-08-11 | $5.63M 10-K · filed 2026-03-05 |
| 2025-09-30 | $1.10M 10-Q · filed 2025-11-04 | $2.34M derived: sum of 2 quarters · filed 2026-08-11 | $3.95M 10-Q · filed 2025-11-04 | $5.76M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.24M 10-Q · filed 2026-08-11 | $2.85M 10-Q · filed 2026-08-11 | $4.67M derived: sum of 3 quarters · filed 2026-08-11 | $6.47M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.61M 10-Q · filed 2026-05-13 | $3.43M derived: sum of 2 quarters · filed 2026-05-13 | $5.24M derived: sum of 3 quarters · filed 2026-05-13 | $7.31M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.62M derived: sum of 2 quarters · filed 2026-03-05 | $5.69M derived: sum of 3 quarters · filed 2026-03-05 | $7.89M 10-K · filed 2026-03-05 |
| 2024-09-30 | $1.81M 10-Q · filed 2025-11-04 | $3.88M derived: sum of 2 quarters · filed 2025-11-04 | $6.08M 10-Q · filed 2025-11-04 | $8.31M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $2.07M 10-Q · filed 2025-08-05 | $4.27M 10-Q · filed 2025-08-05 | $6.50M derived: sum of 3 quarters · filed 2026-03-05 | $8.38M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $2.20M 10-Q · filed 2025-05-12 | $4.43M derived: sum of 2 quarters · filed 2026-03-05 | $6.30M derived: sum of 3 quarters · filed 2026-03-05 | $7.75M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $2.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $4.11M derived: sum of 2 quarters · filed 2026-03-05 | $5.56M derived: sum of 3 quarters · filed 2026-03-05 | $6.62M 10-K · filed 2026-03-05 |
| 2023-09-30 | $1.87M 10-Q · filed 2024-11-06 | $3.32M derived: sum of 2 quarters · filed 2024-11-06 | $4.38M 10-Q · filed 2024-11-06 | $4.97M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $1.45M 10-Q · filed 2024-08-07 | $2.51M 10-Q · filed 2024-08-07 | $3.10M derived: sum of 3 quarters · filed 2025-02-27 | $3.45M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.06M 10-Q · filed 2024-05-08 | $1.65M derived: sum of 2 quarters · filed 2025-02-27 | $2.00M derived: sum of 3 quarters · filed 2025-02-27 | $2.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $591.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $941.00K derived: sum of 2 quarters · filed 2025-02-27 | $1.24M derived: sum of 3 quarters · filed 2025-02-27 | $1.46M 10-K · filed 2025-02-27 |
| 2022-09-30 | $350.00K 10-Q · filed 2023-11-08 | $647.00K derived: sum of 2 quarters · filed 2023-11-08 | $865.00K 10-Q · filed 2023-11-08 | $1.06M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $297.00K 10-Q · filed 2023-08-07 | $515.00K 10-Q · filed 2023-08-07 | $711.00K derived: sum of 3 quarters · filed 2023-08-07 | $802.00K derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $218.00K 10-Q · filed 2023-05-09 | $414.00K derived: sum of 2 quarters · filed 2023-05-09 | $505.00K derived: sum of 3 quarters · filed 2023-05-09 | $609.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $196.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $287.00K derived: sum of 2 quarters · filed 2023-03-27 | $391.00K derived: sum of 3 quarters · filed 2023-03-27 | $495.00K 10-K · filed 2023-03-27 |
| 2021-09-30 | $91.00K 10-Q · filed 2022-11-10 | $195.00K derived: sum of 2 quarters · filed 2022-11-10 | $299.00K 10-Q · filed 2022-11-10 | $370.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $104.00K 10-Q · filed 2022-08-10 | $208.00K 10-Q · filed 2022-08-10 | $279.00K derived: sum of 3 quarters · filed 2022-08-10 | $229.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $104.00K 10-Q · filed 2022-05-11 | $175.00K derived: sum of 2 quarters · filed 2022-05-11 | $125.00K derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | $71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $21.00K derived: sum of 2 quarters · filed 2022-03-28 | $108.00K 10-K · filed 2022-03-28 | |
| 2020-09-30 | -$50.00K 10-Q · filed 2021-11-09 | $37.00K 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |